Literature DB >> 2441206

Coronary vasoconstriction in experimental myocardial ischemia.

G Ertl.   

Abstract

The possibility of a coexistence of coronary arteriolar constriction mediated by the renin-angiotensin system and myocardial ischemia was evaluated. Left anterior descending coronary artery was cannulated and perfused at normal (mean aortic), intermediate (50 mm Hg), and low (30-40 mm Hg) pressure in analogy to a progressive coronary stenosis. Lactate production was present at low coronary pressure indicating myocardial ischemia. In control animals (n = 18), mean coronary conductance was higher (p less than 0.005) at intermediate than at high coronary pressure consistent with autoregulation at coronary flow. Coronary conductance was lower (p less than 0.05) at low than at intermediate coronary pressure, indicating coronary constriction during myocardial ischemia. Adenosine (20 micrograms/kg per min i.c., n = 6) resulted in higher coronary conductance, suggesting coronary vasodilator reserve even at low coronary pressure. Indomethacin (5 mg/kg i.v., n = 12) resulted in low coronary conductance; however, the increase at intermediate (autoregulation) and the decrease (constriction) at low pressure was maintained. Plasma renin activity increased, and saralasin (0.1 microgram/kg per min i.c.) and captopril (0.25 mg/kg i.v.) acted as coronary vasodilators in various models of myocardial ischemia. Captopril limited myocardial infarct size at 6 hours of coronary occlusion, diminished flow repayment and prevented lactate production after 30 s of coronary occlusion, and abolished the deterioration of myocardial function during myocardial ischemia induced by coronary hypoperfusion and atrial pacing. Thus, myocardial ischemia does not generally represent a state of maximal coronary dilatation. The renin-angiotensin system is activated by myocardial ischemia and may exert a coronary constrictive tone. Captopril was beneficial in experimental myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441206     DOI: 10.1097/00005344-198700002-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Control of coronary blood flow by autacoids.

Authors:  E Bassenge
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 2.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 3.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  The renin-angiotensin system and the heart: a historical review.

Authors:  S J Cleland; J L Reid
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  ACE inhibitors for the treatment of myocardial ischemia?

Authors:  C Linder; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 6.  Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.

Authors:  G Heusch; J Rose; T Ehring
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  Calcium antagonists in myocardial ischemia/reperfusion--update 2012.

Authors:  Petra Kleinbongard; Theodor Baars; Gerd Heusch
Journal:  Wien Med Wochenschr       Date:  2012-06-14

8.  Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine.

Authors:  H Ikram; C J Low; T M Shirlaw; S G Foy; I G Crozier; A M Richards; N S Khurmi; R J Horsburgh
Journal:  Br Heart J       Date:  1994-01

9.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

10.  Comparison of the Therapeutic Effects of Acupuncture at PC6 and ST36 for Chronic Myocardial Ischemia.

Authors:  Li Shi; Jiliang Fang; Jiping Zhao; Guiyong Liu; Qing Zhao; Jinling Zhang; Jinzhao Zhang; Bing Zhu; Fanrong Liang; Peijing Rong
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-16       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.